Adjuvant intra-arterial lipiodol-iodine-131 for resectable hepatocellular carcinoma: a prospective randomised trial
- 1 March 1999
- journal article
- clinical trial
- Published by Elsevier BV in The Lancet
- Vol. 353 (9155), 797-801
- https://doi.org/10.1016/s0140-6736(98)06475-7
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Superselective Intra-Arterial Radiometabolic Therapy With I-131 Lipiodol in Hepatocellular CarcinomaClinical Nuclear Medicine, 1996
- Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinomaBritish Journal of Surgery, 1996
- Prognostic significance of pathologic features of hepatocellular carcinoma a multivariate analysis of 278 patientsCancer, 1995
- Small hepatocellular carcinoma: high dose internal radiation therapy with superselective intra-arterial injection of I-131-labeled LipiodolCancer Chemotherapy and Pharmacology, 1994
- Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinomaCancer, 1993
- Intrahepatic Recurrence After Resection of Hepatocellular Carcinoma Complicating CirrhosisAnnals of Surgery, 1991
- Prognostic factors after hepatectomy for hepatocellular carcinomas. A univariate and multivariate analysisCancer, 1990
- Postoperative Recurrence of Hepatocellular CarcinomaAnnals of Surgery, 1990
- Natural history of hepatocellular carcinoma and prognosis in relation to treatment study of 850 patientsCancer, 1985
- The surgical management of primary carcinoma of the liverWorld Journal of Surgery, 1982